InventisBio Co., Limited (SHA:688382)
China · Delayed Price · Currency is CNY 21.34
-0.70 (-3.18%)
At close: Apr 21, 2026
InventisBio Revenue
In the year 2025, InventisBio had annual revenue of 37.29M CNY, down -77.91%. InventisBio had revenue of 6.40M in the quarter ending December 31, 2025, a decrease of -95.73%.
Revenue
37.29M
Revenue Growth
-77.91%
P/S Ratio
341.83
Revenue / Employee
201.57K
Employees
168
Market Cap
12.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.29M | -131.50M | -77.91% |
| Dec 31, 2024 | 168.79M | -16.74M | -9.02% |
| Dec 31, 2023 | 185.53M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Chengzhi | 10.87B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Aurisco Pharmaceutical | 1.70B |
| Vcanbio Cell & Gene Engineering Corp., | 1.47B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 1.20B |